Heptares and PeptiDream Collaborate on Inflammatory Disease Therapeutics

Pharmaceutical Technology Editors

The collaboration will focus on the discovery, development, and commercialization of novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) that plays an important role in inflammatory diseases.

Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corporation, and Tokyo-based biopharmaceutical company PeptiDream have entered into a strategic collaboration to discover, develop, and commercialize novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) that plays an important role in inflammatory diseases.

Heptares will apply its StaR platform and resulting 3D structural insights to the GPCR target selected by both companies. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against the target GPCR and to optimize hit peptides and/or small molecules for further development.

Under the agreement, the companies will jointly conduct and share the costs of the discovery and development program, and will co-own any resulting products. No financial details were disclosed.

Source: Heptares